Yahoo Web Search

Search results

1. • 

     Bristol Myers Squibb reports setback in lung cancer trial By Investing.com

     Investing.com· 6 days ago

     The study evaluated the efficacy of...subsequent treatment with Opdivo plus Yervoy, in patients with...

2. • Candel Lights Up Investors' Portfolio With 830% Gain

     RTT News· 16 hours ago

     Shares of Candel Therapeutics Inc. (CADL) have gained more than 830% in the past 2 months, thanks to the substantial progress achieved across its clinical programs.

3. • Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study

     Zacks· 4 days ago

     The phase III CheckMate -73L study evaluated Opdivo with concurrent chemoradiotherapy (CCRT) followed by Opdivo plus Yervoycompared with CCRT...

4. • 

     Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

     Zacks via Yahoo Finance· 2 days ago

     With Merck’s growth largely depending on Keytruda...pipeline setbacks do not bode well for the...

5. • 

     Pre- and post-surgical immunotherapy improves outc | Newswise

     Newswise· 3 days ago

     Results from the Phase III CheckMate 77T study were published today in the New England Journal of...

6. • Q1 2024 TRACON Pharmaceuticals Inc Earnings Call

     Thomson Reuters StreetEvents via Yahoo Finance· 1 day ago

     The two arm trial will enroll 78 patients...durvalumab maintenance treatment. The primary endpoint of the trial is progression-free survival, and the trial is designed to ...

7. • MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim...

     Morningstar· 7 days ago

     Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at 4:30 p.m. ET ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ

8. • Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by...

     Benzinga· 4 days ago

     The approval is based on the pivotal TRIDENT-1 trial, in which AUGTYRO achieved a high response rate and durable responses, including robust intracranial responses Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today

9. • Small Business - The Andalusia Star-News | The Andalusia Star-News

     The Andalusia Star-News· 3 days ago

     — Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengrui’s

10. • What Can Black Seed Oil Do for Your Health?

      Mercola· 1 day ago

      Black seed oil is regarded for its potential to help protect against diseases and heal ailments — it has antidiabetic, analgesic, anti-inflammatory, antimicrobial and antioxidant properties, ...